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Having investigated all the essential amino acids, withdrawal of
arginine (–Arg) was least tolerated by tumour cells (HeLa) in vitro
(Wheatley et al, 2000). Because Arg cannot normally be synthe-
sized by cultured cells, it is an essential amino acid. Most essential
amino acids have relatively uncomplicated metabolisms related
principally to protein synthesis, as typified by Leu (Neff et al,
1977). However, the rapid metabolism of Arg through many
different pathways reduces its availability in culture faster than
other amino acids (Wheatley et al, 2000; see also Discussion).
Furthermore, Arg is less efficiently re-utilized from catabolized
proteins than Leu or Lys (Wheatley et al, 2000). Its withdrawal
also leads to a more flagrant ‘pleiotypic response’ (Rabinovitz,
1992) than found with deficiencies of other amino acids. This
greater ‘demand’ on Arg is still not fully appreciated by cell
culturists (see Daniel and Krishnan, 1968; Paul and Walters,
1974), although Eagle (1955; 1959) did note that his chosen cell
lines required additional Arg supplementation in the early ‘optimal
growth’ studies. Indeed, the arginine problem is better appreciated
in whole animal growth studies (Wu and Morris, 1998).
Removal of one or more of any of the 11 essential amino acids
might be expected to produce similar biological end-points in cell
cycling both of normal and malignant phenotypes, but this is not
so. A rapid demise of tumour cells occurs in Arg-free (–Arg)
medium, whereas diploid fibroblasts move into quiescence, a
differential which clearly offers a selective advantage in targeting
tumour cells (Wheatley et al, 2000). Tumour cells, unlike their
normal counterparts, initiate further rounds of replication
following deprivation and fail to enter quiescence, as seen with
KB (a human cervical carcinoma cell line; Weissfeld and Rouse,
1977a–c). For this reason they cannot be synchronized by this
procedure, whereas normal cells and occasionally others can, e.g.
CHO, a fibroblastic cell line from the Chinese hamster ovary
(Tobey and Ley, 1970).
Synchrony is more often induced in cell culture by reducing
serum to low concentration. The culture medium has a fully nutri-
tional complement, but lacks essential growth factors required 
for cell-cycle progression. Cells arrest at the mid-G1 checkpoint
(Pardee, 1974; 1989), where they accumulate and can be released
to initiate S-phase synchronously when serum is restored. In
contrast, removal of an essential nutrient leaves the growth factors
in place, but restricts growth and cell cycling by inhibiting de novo
protein synthesis. Malignant and transformed cells lacking strin-
gent G1 control, however, try to continue cycling, a fundamental
difference which should be eminently exploitable as a means of
selectively killing tumour cells.
In this comparative study of 26 selected cell lines (Table 1),
cells of human origin have mostly been used, because the aim will
eventually be to test the efficacy of deprivation on primary tumour
cell lines taken from patients prior to in vivo treatment. Murine
and a few other species have been included because comparative
in vivo studies are in progress in animal models, and certain mole-
cular biology experiments are feasible only in special cell lines,
e.g. Mv1Lu (mink lung cells; see Lamb, 1998). Investigators have
already shown the poor tolerance of malignant cells in vivo to Arg
deprivation, e.g. in the murine leukaemic cell lines, L5178 (Storr
and Burton, 1974) and L1210 (Ormerod et al, 1994). The implica-
tions of our present findings with regard to the treatment of human
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lowering Arg has been considered for years to be a potential thera-
peutic method (Bach and Swaine, 1965; Yeatman et al, 1991;
Wheatley, 1998). The efficacy of Arg deprivation as an in vivo
treatment ultimately depends on the rapidity with which tumour
cells in general succumb. We are addressing this problem in vitro
initially, in order to identify which tumour types are the more
sensitive to deprivation, and also to measure the degree to which
resistance types are found. These studies should help to refine an
effective Arg deprivation protocol which will lead to a more
rational and selective means of tumour therapy in vivo.
MATERIALS AND METHODS
Cell lines
HeLa and HeLa S-3, IBR3G and IBR3T, A549, KHOS/NP,
MOLT4, HL 60, WiDr, B16-F10, NIH 3T3, GO-G-CCM, U-87-
MG, PC3 and A431 cells were purchased from the European
Collection of Animal Cell Cultures (Porton Down, Salisbury, 
UK). Normal human diploid fibroblasts (MG2F and FF) were
established from adult skin and neonatal foreskin, respectively,
obtained from the surgical theatres at The Royal Aberdeen
Hospitals Trust. Mouse fibroblasts (3T3) and SV40 transformed
fibroblasts (3T3-SV40) were provided by Professor Anders
Zetterberg (Institute of Tumour Biology, Karolinska Institute,
Stockholm, Sweden). 3T3/BIBR were obtained originally from the
former British Industrial Biological Research Institute (London,
UK). Human breast carcinoma cells MCF-7 and ZR 75-1 were
generously provided by Professor Arthur Pardee and Dr Debajit
Biswas (Dana-Farber Cancer Institute, Boston, MA, USA). The
human osteosarcoma cell lines, U20S and Saos-2, were from Dr
Lindsey Allen (Imperial Cancer Research Foundation, London,
UK), and the human ovarian carcinoma line, PEO1, from Dr
Simon Laing (University of Edinburgh, UK). Mink lung epithelial
cells (Mv1Lu) were from Dr Mark Ewen (Dana–Farber Cancer
Institute), PtK1 cells were provided by Dr Sam Bowser
(Wadsworth Laboratories, Empire State Plaza, Albany, NY, USA).
All cells tested free of mycoplasm before they were used, and none
were cultured beyond five passages from the stock cultures held,
which was normally just one passage on from the cells obtained
from our sources.
For comparative work, most cell lines were grown in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
fetal calf serum (FCS) (both GIBCO/BRL), 100 µ g ml–1 strepto-
mycin sulphate (Sigma) and 100 U ml–1 penicillin (Britannia
Pharmaceuticals) at 37° C in a humidified atmosphere of 5% CO2.
The medium for several cell types, notably the leukaemic types
(see Table 1), was RPMI 1649, but growth was not appreciably
different in DMEM.
Arginine deprivation experiments
After exponential growth had been established, cultures were
washed with phosphate buffered saline (PBS) and incubated with
either complete medium (+Arg) or medium deficient in L-arginine
(–Arg), both containing 5% dialysed (> 10 kD) serum (Sigma).
Media were prepared in accordance with published formulations,
the appropriate amino acids being left out as required.
Co-cultures
Cultures of mixed tumour and normal cells were set up as
indicated in the text. The ratios of the cell types were varied from
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Table 1 Effect of Arg deprivation of normal and malignant cell lines in culture
Cell line Species Type Malignant/ Fate in –Arg* Time of death
normal of culture**
MG2F human adult skin fibroblast normal Q (> 20 days) –
FF5/15 human neonatal foreskin fibroblasts normal Q (> 28 days) –
IBRI3 human fibroblasts normal Q (> 10 days) –
IBR3G human fibroblasts transformed 36 h 6 days
HeLa human cervical carcinoma malignant 36 h 3 days
A431 human squamous arcinoma malignant 24 h 3 days
MCF7 human breast carcinoma malignant (?) Q –
ZR75-1 human breast carcinoma malignant 48 h 4–5 days
PEO human ovarian carcinoma malignant 48 h 3–4 days
PC3 human prostatic carcinoma malignant 48 h 3 days
WiDr human colon carcinoma malignant 36 h 4–5 days
A549 human lung carcinoma malignant (?) Q –
KHOS/NP human osteosarcoma malignant 36 h 5 days
U2OS human osteosarcoma malignant 48 h 3 days
Saos 2 human osteosarcoma malignant 3 days 5 days
GO-C-CCM human glioma/astrocytoma malignant 48 h 4–5 days
U-870-MG human glioblastoma malignant 48 h 4–5 days
HL60 human premyelocytic leukaemia malignant 24 h 2 days
MOLT4 human lymphoblastic leukaemia malignant 24 h 2 days
3T3 (NIH) murine fibroblasts ‘normal’ (see text) 3 days 4–5 days
3T3 (BIBR) murine fibroblasts ‘normal’ (see text) 3 days 4–5 days
3T3 murine fibroblasts ‘normal’ (see text) 3 days 4–5 days
3T3 SV40 murine SV40 transformation of above transformed 48 h 3 days
B16-F10 murine melanoma malignant 48 h 5 days
Mv1Lu mink lung ‘normal’ Q –
PtK1 kangaroo rat kidney epithelial ‘normal’ Q (> 7 days) –
Q = quasi-quiescence; *time at which clear evidence of cell death was found; **time at which cells were irrecoverably lost and/or deadequivalence up to an excess of tumour cells at a ratio of 8:1, in
order to explore the full potential of arginine deprivation on the
preferential elimination of tumour cells.
Cell proliferation
This was monitored by cell counting using a Coulter electronic
particle counter. The monolayer was washed with PBS and the
cells were detached with 0.2% trypsin (Sigma). The trypsin was
neutralized with DMEM containing 10% FCS. In each experiment
three samples were counted at each time-point and the mean value
± 1 SD calculated. After periods of deprivation, cell cultures were
rescued from –Arg conditions in complete medium containing
10% undialysed FCS to check the recovery kinetics.
Flow cytometry
Analyses of cell-cycle phase distribution and DNA synthesis
(DNA content/BrdU incorporated) were made using the method of
Dolbeare et al (1983). Cells were labelled with 100 µ M 5-bromo-
2′ -deoxyuridine (BrdU) (Sigma) for 30 min at 37° C before being
fixed in 70% ethanol. Following denaturation with 2 N HCl
containing 0.5% Triton X-100 (Sigma), the cells were stained with
anti-BrdU-FITC (Becton Dickinson) and propidium iodide
(Sigma). DNA content and incorporated BrdU were measured
using an EPICS Profile II Coulter electronics flow cytometer, no
less than 20 000 events were processed per sample and the bitmap
was adjusted to exclude the counting of doublets.
Cell viability
This was assessed using an MTT assay (Mosmann, 1983). Cells
were incubated with 5 mg ml–1 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) (Sigma) for 4 h at 37° C. The
cleavage product formazan was then solubilized with 0.04 N HCl
in isopropanol for 30–60 min and absorbance was measured on a
spectrophotometer with dual filters of 540 nm and 690 nm.
Electron microscopy
Electron micrographs were obtained conventionally after fixation
of cells in medium without serum containing 2.5% glutaraldehyde
at room temperature for 20 h, followed by dehydration through to
absolute alcohol, Epon embedding and finally sectioning at 800 Å
with a Diatome knife. The sections were mounted on uncoated
copper grids and stained with lead citrate and uranyl acetate before
being viewed at 60 kV in a Jeol 100S electron microscope.
RESULTS
Cell proliferation
Growth curves for nine of the cell lines in Table 1 are set out in
Figure 1. Although no cells thrive in the absence of arginine,
responses showed two distinct patterns. Each of the cell lines
shown in Figure 1 has been included, however, because additional
features and idiosyncrasies will be discussed below, and/or are the
subject of in vivo studies currently in progress. One group of the
cell lines arrested and showed little diminution in cell number over
the ensuing period of several days to weeks, while the other group
showed a rapid loss of cell number, often falling below the initial
level and many dropping to near zero within a few days. Normal
cell lines fit the former category (Figure 1A; this response is also
typical of MG2F, FF, PtK1 and Mv1Lu, which will be discussed
below for their own particular experimental value), whereas the
overwhelming majority of the malignant or transformed cell types
fit the latter category (Figure 1 D–I), with the two notable excep-
tions (Figure 1B and C). The reason for the ‘resistance’ of MCF7
and A549 cells almost certainly holds the key to an understanding
of the underlying molecular disturbances responsible for demise of
the sensitive tumour cell lines. The data in Figure 1 does not go
beyond 5 days of deprivation, by which time all cells of the
susceptible cell lines (Figure 1 D–I) were irrecoverable.
Cell death
Cell death occurred within the first 5 days of deprivation in the
sensitive malignant cell types, many cultures showing complete
involution within 3 days, with the leukaemic lines HL60 and
MOLT 4 being almost completely obliterated within 2 days (Table
1). Apart from these two, morphological evidence of death was not
usually obvious before 24 h, but appeared during the second day
of exposure (Figure 2), when cells started rounding up and lifting
off the substratum before disintegrating in the culture medium.
Their changes were suggestive of lytic cell death rather than apop-
tosis, and there has been no consistent indication that the latter
mechanism is necessarily involved in other cell lines. Closer
inspection of the process by electron microscopy reveals that the
first changes are in the periphery of the nucleus with more ‘castel-
lation’ of chromatin being observed by about 12–16 h, and with
nucleoli becoming more reticular (Figure 2B; see also Figure 12 in
Wheatley et al, 2000). This is followed at 24 h by small blebs
appearing on some cells (Figure 2C), but these blebs resolve and
the outer regions of the whole of the cytoplasm take on a more
translucent appearance and include more lipid droplets in cells in
which the outer membrane has completely smoothed off by 36 h
(Figure 2D). Some cells show signs of condensation of the
cytomatrix (Figure 2D), but this is not a general feature.
Phagosome/lysosome activity is greatly increased from 24–36 h,
and by 48 h a mixture of totally dead cells, completely pycnotic
cells and some almost normal-looking cells begins to appear
(Figure 2E). Thereafter, the cells become increasingly lytic in their
cell-death appearance.
Representative examples of the main differences between the
normal and malignant cell responses to Arg deprivation are shown
in Figure 3. In cultures such as HeLa, ZR 75-1 and KHOS, a few
very large (multinucleate) cells were the only survivors after 3–4
days but could not be rescued in +Arg medium by this time.
In ‘normal’ cell lines, quiescence was usually reached within
24–36 h, with only a small increase in cell number during the first
day, after which the majority of cells remained intact and appar-
ently viable for several weeks under these conditions, particularly
when cultures were given regular changes of –Arg medium. The
effects of restoring Arg between days 1 and 7 of deprivation for
human diploid fibroblasts and HeLa cells are contrasted in Figure
4. The severity of metabolic depression by cells, measured 3 days
after the start of –Arg treatment of several cell lines, was reflected
in the MTT test of cellular (mitochondrial) activity (Figure 5),
included here because this is a frequently used cytotoxicity assay
in tumour cell sensitivity screening. Figure 5 demonstrates its
802 L Scott et al
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amino acid deprivation studies on cancer cells; PC3 and H60 cell
lines, for example, which rapidly succumb to –Arg, gave MTT OD
540 levels of ~0.05 or less (= ‘undetectable’) within 3 days.
Tumour cells surviving in –Arg medium (A549 and MCF7) show
different metabolic activity levels, although most cells left at day 3
were not disintegrating like most other tumour cell lines.
Table 1 shows that the ‘matched pair’ of established cell lines,
IBR3 and IBR3G (the latter being a transformed subline of the
former) have quite different fates; the former becomes quiescent,
whereas transformed cells die within 5 days (Figure 6). In a similar
matched pair comparison, 3T3 cells were found to die relatively
quickly in –Arg conditions, being not as fast as its virally trans-
formed subline, 3T3-SV40. NIH 3T3 and BIBR 3T3 were equally
sensitive (Table 1, see also Tanaka et al, 1988) to the former cell
type. Thus 3T3 cells behave in the manner of transformed lines,
unlike IBR3 fibroblasts (see Discussion). The Mv1Lu line was
included because transfectants can be made with a truncated cdk4
cDNA which stably express cdk4 (Mv1Lu-B7 and Mv1Lu-H5,
Ewen et al, 1995). The parental line can be downregulated in –Arg
(Table 1), and behaves like a well-regulated (normal) cell type,
whereas the tranfectants do not, showing a cell cycle ‘freeze’ in
–Arg (for data on these transfectants, see Lamb, 1998 and
Discussion).
Flow cytometry
Although analyses of 90% of the cell lines used here were
performed, Figure 7 gives data on five carefully selected lines
which are representative examples of the more interesting changes
Arginine deprivation kills tumour cells 803
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Figure 1 Growth curves of nine of the 26 cell lines used in this study. They are each representative of the various responses of different cell types to –Arg
medium. In the top row, cells in exponential growth were changed to –Arg medium and within ~24 h were downregulated and ceased to proliferate, cell number
remaining relatively constant for > 5 days. Much greater variation was found in the cell counting with MCF7 cells (C), than in normal fibroblasts (A) or A549 cells
(B). (B) and (C) show the two ‘exceptional examples’ of malignant phenotypes responding by downregulation in the face of Arg deprivation (see text), and
(D)–(I) are representative of susceptible mouse and human malignant lines which do show some different kinetics of demise (see text)804 L Scott et al
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Figure 2 Transmission electron micrographs of HeLa cells exposed as follows: (A) 24 h to +Arg medium (control), (B) 24 h to –Arg medium, beginnings of
castellation at the nuclear periphery; (C) 30 h to –Arg medium, with some surface blebbing (arrows); (D) 36 h to –Arg, now with some smoother cell profiles
(filled arrows), but with darker smaller cells as well (open arrow); (E) 60 h to –Arg; a general view showing the variety of appearances of dead cells, mostly lytic
(open arrow), but a few cells retaining more normal appearances (filled arrows). Note the highly pycnotic nucleus in the central cell and the intense lysosomal
activity in the cytoplasm. Magnifications: A, B and D: × 4000; C: × 2500; E: × 7500
Figure 3 Photomicrographs of control cultures given +Arg medium (left column) and grown for 3 days compared with parallel cultures given –Arg medium for
the same period. (A) and (B) B16-F10; (C) and (D) ZR-75-1, note the large multinucleated cells persisting to the right in (D), in this cell line 4–5 days are needed
before the cells finally die. (E) and (F) MCF7 cells, with the highly retracted bodies of the deprived cell in the latter frame showing persistence not just for 3 days
as here, but for considerably longer than other malignant lines. (G) and (H) A431 cells, which is a most sensitive cell line. Magnification approximately × 125Arginine deprivation kills tumour cells 805
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Figure 4 Graphs showing the degree of recovery of (A) HeLa cells or (B) normal fibroblasts (MG2F) from exposure to –Arg since the zero-hour time-point until
+Arg medium was restored. In (A), this was at 0 (  ), 1 (  ), 2 (   ), or 3 (  ) days, with (   ) as the non-recovered negative control population. In (B) the symbols
refer to: 2 (  ), 4 (   ), and 5 (  ) days of –Arg before recovery was initiated with +Arg medium, and (∆ ) shows recovery from 7-day exposure, which was slower
than with the shorter exposures.
Figure 5 MTT assays in terms of colour generation per unit mass of cells,
with the control (+Arg) value (absorbance at OD540 = 0.58) being taken as
100%. The more resistant cells remaining intact (MCF7 and MG2F) show
sustained ability to convert the substrate after 3 days in –Arg medium,
whereas the malignant cell lines were down to 20% or below the control
value. Values are means of six estimates ± 1 SD
Figure 6 IBR3 fibroblasts cultured in medium with and without Arg for 3
days. (A) Normal IBR3 cells in +Arg; (B) Same in –Arg medium; (C) the
virally transformed subline IBR3G after 3 days in +Arg; (D) same after 3 days
in –Arg medium. In (B) the number of cells present was approximately the
same as when the cells were initially set up. Magnification approximately 
× 200806 L Scott et al
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cycling
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Figure 7 Bivariate flow analysis of the effects of –Arg over the first 3 days of exposure relative to the normal cycling (+Arg) controls for five representative cell
lines of those shown in Table 1. While normal cells (FF5/15) in S-phase manage to scavenge enough free Arg to move through S, G2 and M back into G1, no
cells move from G1 into S-phase labelling (shown by the absence of the elevated part of the ‘horseshoe’ distribution on left, top of column A), A549 (B)
remained almost unchanged in the frequency distribution profile, i.e. in a cell-cycle ‘freeze’, in which by 48 h they were not actively synthesizing DNA. MCF7
cells (C) did slowly move on through cycle, but by 72 h there was a noticeable increase in the debris to the left, as also in the case of HeLa (D). HeLa continued
to synthesize DNA, which was to their severe detriment by 72 h. In U2OS (E), a similar pattern to HeLa cells was found
A B
C D
Figure 8 Co-cultures of MGF2 and WiDr cells were exposed to medium
with and without Arg. (A) The fibroblasts were set out at this density and
seeded with WiDr cells to grow for 3 days, by which time the co-cultures
looked like (B). At this time, half the cultures were switched to –Arg medium,
and the other half continued in fresh +Arg medium. The latter co-cultures
overgrew and could not be sustained more than 2–3 days more, with little
change in from (B). In (C), the co-culture had been in –Arg medium for 3
days, at which time only a few small ‘nests’ (arrow) of tumour cells were left.
Cultures which had reached state (C) were given +Arg medium and a further
2 days later (D) we see fibroblast regrowth and no evidence of any sustained
WiDr repopulation. Magnification × 125
A
B
C
Figure 9 Evidence of selective elimination of B16-F10 cells co-cultured with
FF5/15 fibroblasts by flow cytometry. Twice as many melanoma cells as
fibroblasts were seeded into cultures and examined after establishment as a
50–60% confluent monolayer within 2 days (A). After 36 h in –Arg, the B16-
F10 pattern had radically altered (black), and showed signs of degeneration
(particles towards the ordinate axis), whereas the fibroblasts had left S and
accumulated mostly in G1, although a good G2 peak was also seen at this
time. (B) By 72 h in –Arg, the fibroblasts were almost exclusively in G1,
whereas some B16-F10 cells remaining intact occupied largely their G1
position, but the majority had degenerated. (C) By 5 days, all the B16-F10
had become small debris particles close to the ordinate.seen in cell-cycle dynamics and distributions in this study. In the
two ‘resistant’ malignant cell lines, A549 and MCF7 (see also
Figure 3E and 3F for the latter), a cell-cycle ‘freeze’ was
confirmed by their flow cytometric analysis at 24, 48 and 72 h of
exposure (Figure 7B and 7C). The cells could be recovered after
10 days in –Arg, although by that time cell number had inevitably
fallen slightly. After the rescued cells had grown to 60% conflu-
ence, they were exposed to a second episode of –Arg, to which
they responded in the same manner as to the first episode, although
a smaller percentage of cells survived for as long as 10 days
following the second episode.
While the A549 and MCF7 cell lines showed arrest, it was by
no means as clean as arrest of normal human fibroblasts which
classically piled up in G. However, the fact that these tumour
lines can stop all around the cycle contrasts strongly with virtu-
ally all the other malignant cell lines, which rapidly died. The
paradigm here is HeLa (Figure 7D), to which similar traces were
recorded for A431, B16 F10, WiDr and the many other estab-
lished tumour cell lines. The death of these cells occurs as a
consequence of their remaining in cycle with greatly protracted
S- and G2-phases, unable to complete S-phase and dying in a
premitotic catastrophe.
Co-cultures
Selective death of malignant cell type was most readily apparent in
co-cultures (Figure 8, Warrington, 1978). More than six different
combinations of malignant and normal cells have been admixed,
and survival of both malignant and normal cells only observed
when the former were not susceptible to cell death under –Arg
conditions (e.g. A549 co-cultured with normal diploid fibroblasts).
We have taken seeding ratios as high as 8 times the malignant cell
line to normal cells, and found that the former were almost
completely decimated within 3–4 days, with virtually no loss of
fibroblasts. A typical result from an admixture of roughly equal
(starting) numbers of human fibroblasts (FF5/15) with B16–F10
melanoma cells has also been followed using flow cytometry,
since the frequency distribution patterns are quite distinct and
clearly show the selective death of the tumour cell line (Figure 9).
DISCUSSION
Responsiveness to Arg deprivation compared with
other amino acid deficiencies
Analysis of the effects of deprivation of each of the eleven essential
amino acids in turn on the number of lines used in this study would
be prohibitively burdensome, but we have in fact checked many
besides Arg. The data so far continues to be fully consistent with our
previous findings (Wheatley et al, 2000), lending further support to
the idea that most tumour cell lines die considerably more quickly
during Arg deprivation than in the absence of any other single (or
group of) essential amino acids. For this reason, we focused exclu-
sively on Arg deprivation in the present study. Furthermore, Arg
begins to become limiting at ~10–4 M, whereas other amino acids
can sustain growth at 10–5–10–6 M (Wheatley et al, 2000).
Loss of viability associated with checkpoint
derangement in tumour lines
We have shown (Wheatley et al, 1993; 2000) that the loss of
viability in most of the malignant phenotypes reflects derangement
Arginine deprivation kills tumour cells 807
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Figure 10 Schema of some of the more typical involvements of arginine in cell metabolism. The frequent use of arginine as a source of precursor in pathways
leading towards pyrimidine and purine synthesis have not been includedof control primarily at the key G1 checkpoint, which normally
prevents cells from reinitiating DNA synthesis under adverse
circumstances. In the majority of transformed cell lines, i.e. other
than our two notable exceptions, cells which nevertheless
remained intact after 1 week of deprivation were invariably multi-
nucleated large cells which were irrecoverable in +Arg medium.
Thus, not only is the overwhelming majority of tumour lines
susceptible to Arg deprivation, but cell death occurs without any
further intervention. Our two exceptional lines will, however,
prove invaluable in pinpointing the molecular aberrations of the
cell-cycle engine responsible for the demise of the susceptible
types (see below).
Our findings with 3T3 cells fully support those of Tanaka et al
(1988), who showed that NIH 3T3 cells die in Arg deprivation, as
do supposedly related 3T3 ‘sublines’ (Table 1). Since 3T3 cells are
so widely used in serum step-down cell-cycle studies, their
response to amino acid deprivation indicates a lack of R-point
stringency, although the ability to induce synchrony following
serum deprivation has always suggested otherwise. Thus the
requirement for serum factors may be more crucial for the move-
ment of transformed cells from G1- into S-phase than the presence
of essential amino acids, which is in keeping with the ability of
other established cell lines to be parasynchronized by serum depri-
vation (Rubin and Xu, 1991; Yin and Wheatley, 1994), but inter-
estingly not by amino acid withdrawal. In well-regulated cells,
serum and amino acid deprivation are supposed to map temporally
to the same G1 point (Yen and Pardee, 1978; Lamb and Wheatley,
2000), but these findings suggest otherwise.
Cycling differences shown by flow cytometry
‘Obedient’ cells placed in arginine-deficient medium are either
arrested within about 5–6 h from further entry into S-phase
(Lamb and Wheatley, 2000), or if they have already passed this
point, they complete the ongoing cycle and enter quiescence
(G0), usually within ~24–30 h. The prolonged survival (>4
weeks) of normal cells (human diploid fibroblasts) is remark-
able, although an initial cell drop-out of ~10% of the total
population is seen within the first 48 h of deprivation, followed
by a much slower, almost imperceptible, decline in total cell
number thereafter. In contrast, susceptible cells continue to re-
enter S-phase, and most of those already started never complete
it. This agrees with the findings of Weissfeld and Rouse
(1977a–c) on KB and CHO cells. Bivariate flow cytometric
analyses (Figure 7) are consistent with these observations. No
cells enter mitosis after even a few hours of being deprived
(Lamb and Wheatley, 2000; Wheatley et al 2000). That
progression to cell death out of S-phase or G2-phase occurs by
way of a premitotic catastrophe, nevertheless, is conjecture and
needs further elucidation.
Loss of constraint at the G1 checkpoint results in continued
cdk4-cyclin D-mediated phosphorylation of retinoblastoma
protein (pRb). In a previous paper, we have described in detail the
dependence of R-point control on the phosphorylation of pRb by
active cdk4-cyclin D complexes in normal fibroblasts (Lamb and
Wheatley, 2000). G1 arrest in response to a number of growth
inhibitory conditions has been shown to be due to repression of
cdk4 (Ando and Griffin, 1995). It is possible that p53 may be
responsible for cdk4 downregulation in the absence of arginine,
since a p53-dependent pathway has been identified in response to
TGF-β -mediated G1 arrest (Ewen et al, 1993; 1995) and p53 is
mutated in most tumour cells. We are currently assessing p53
functionality and determining the levels of cdk4 and p21 as a
consequence of arginine deprivation, using suitable cell lines
including many of those discussed herein and fresh primary
tumour cell cultures (in preparation; see Lamb, 1998; Scott, 1999).
The possibility must also be kept in mind that more than a single
aberration in cell-cycle control will probably be present in highly
malignant phenotypes. For example, it is well known that most
tumours have mutant p53 (see below).
Exceptions to the ‘rule’
A549 and MCF7 did not show the same clean, debris-free appear-
ance of normal cells in –Arg, the proportion of cells dropping out
before the real survivors being considerably greater . Nevertheless,
their ability to survive does not mean that they are devoid of defec-
tive control at cycle checkpoints other than the R-point, just as the
other (susceptible) tumour cells may have multiple derangements.
The nature of their ‘cell-cycle freeze’ needs further investigation,
but it is possible that they avoid mitotic catastrophe by retaining
late-cycle checkpoint stringency, lost in most other tumour cell
types examined. The possibility that the resistant cells have normal
(or at least functional) p53 status has been explored (Scott, 1999),
and indeed preliminary data shows that both A549 and MCF7
have functional p53, unlike the situation in sensitive cell lines
(Scott et al, 1998). The notion, therefore, is that they could be
avoiding the hazard that their mitotic impetus is driving them into
the cell death pathway because they do slowly filter through to G1
of the next cycle.
Implications of selective tumour cell destruction for
cancer therapy
Arg is the first amino acid to be exhausted by normal cell metabo-
lism in culture (Hanss and Moore, 1964). The pathways for which
it is the first or an early substrate are diverse, as shown by a
diagram of its major metabolic involvements (Figure 10). To date
we have explored all the essential amino acids using HeLa cells as
the tumour cell assay (Wheatley et al, 2000), although it remains a
possibility that different cell lines are especially sensitivity to the
lack of certain other amino acids. Methionine can be taken as a
case in point, as shown by Guo et al (1993). However, we are in
general confident that arginine deprivation works better in almost
all tumour lines, and the future strategy for improved cancer treat-
ment will be based specifically on its withdrawal. While this can
easily be achieved in vitro, the same is not true of the in vivo situ-
ation. Nevertheless, if it can be achieved, a clear practical advan-
tage can be gained for a more rational and selective therapeutic
approach to cancer treatment. An added bonus is that, not only
does the poorer regulation of the R-point in malignant cells help to
selectively target cancer cells, but that a remarkably high death
rate follows naturally within a few days of deprivation without the
need for any further intervention.
Some oncologists have recommended Arg supplementation to
enhance cell-kill rate during chemotherapy (Brittenden et al,
1994), supposedly through boosting host immunosurveillance
mechanisms (Hester and Fee, 1995). The case is not proven, and
therefore more consideration ought perhaps be given to arginine
deprivation, which has had a following in the past (Wheatley,
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considered combination treatment for resistant cell types. This we
hope to achieve through the use of very low levels of cycle-
dependent DNA-targeting drugs since the resistant tumour cells,
unlike normal cells, remain in cycle with a preponderance of cells
in S-phase. Our initial findings confirm previous work that an
adequately low-dose level must be carefully chosen, because
there comes a point at which the concentration of a DNA-
damaging cell-cycle-dependent drug will itself slow down or
prevent the re-initiation of S-phase in cells which would 
otherwise have moved on past the G1 checkpoint.
Counterproductively, this introduces an element of protection
rather than an augmentation or enhancement of the cell-killing
effect of –Arg alone (Lamb and Wheatley, 1996). It will therefore
be of interest to see whether Arg-deprived MCF7 and A549 cells
succumb to combined low-dose therapy (Stirrat et al, submitted;
and work in progress).
Some investigators have advocated the combined use of
analogue amino acids (Ryan and Elliott, 1968; Warrington, 1992;
Rabinovitz, 1996). These offer no further benefit because they
affect normal cells as much as malignant cells by their incorpora-
tion into proteins (Wheatley et al, 2000). Treatment with canava-
nine and p-fluorophenylalanine in –Arg and –Phe conditions
respectively actually obfuscate the selectivity gained with –Arg
treatment alone.
In conclusion, lack of Arg alone has such a marked effect on
tumour cells that augmentation with other modalities of treatment
become unnecessary. Most tumour cells die quickly, whereas
normal cells enter quiescence and survive for long periods of
time. Some tumour lines (~10%; e.g. A549 and MCF7 cells)
appear to downregulate activity in response to –Arg, but may
enter a cell-cycle freeze. The sensitivity of primary tumours can
therefore be screened in vitro by testing with the various tech-
niques employed herein, to see whether they are sensitive or resis-
tant to Arg deprivation. If this procedure can be translated to the
in vivo situation, control of Arg levels in animal and human
tumour patients should bring about the demise of cancer even in
disseminated (metastatic) disease.
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